Background: Diabetes is frequently diagnosed in patients with cirrhosis and represents an important risk factor for morbidity and mortality. Pharmacological therapy is limited due to hepatotoxicity and the risk of hypoglycemia. Investigations on medical practice in this patient population, frequency of diabetes-associated complications and the impact of quality of metabolic control are rare. Aims and Methods: A retrospective analysis was performed to compare the effects of hypoglycemic treatment, the achieved glycemic control under therapy, the prevalence of typical cirrhosis-related or microangiopathic complications, and cardiovascular comorbidities between a group of diabetic patients with cirrhosis (n = 87) and a nondiabetic cirrhotic population (n = 198). Results: The prevalence of diabetes in our cohort was 30.5%. Of all diabetic patients, 39.1% received therapy which might potentially result in serious side effects in patients with end-stage liver disease. The rate of ongoing alcohol abuse (28.7%) and noncompliance under medication (41.4%) was high. Only 28.7% of all diabetic subjects showed satisfactory (as defined by HbA1c ≤ 6.5%) glycemic control under therapy. Patients achieving satisfactory control experienced a lower rate of certain cirrhosis-related complications such as hepatic encephalopathy (HE) and hepatocellular carcinoma (HCC), arterial hypertension, and hypercholesterolemia. HE was significantly more frequent in diabetic than nondiabetic cirrhotic patients [HE 36.6% (diabetics) vs. 20.7% (non-diabetics), p = 0.001; ORadj = 3.21 (CI: 1.63, 6.28)], whereas no significant difference in the frequency of HCC [18.4% (diabetics) vs. 14.1% (nondiabetics), p = 0.606] was observed. In the majority of our diabetic population (59.7%), no microvascular damage was diagnosed. However, diabetic patients had a borderline significant high prevalence of arterial hypertension [48.3% (diabetics) vs. 26.8% (nondiabetics), p = 0.078; ORadj = 1.68 (CI: 0.944, 2.978)] and high cholesterol levels [17.2% (diabetics) vs. 8.6% (nondiabetics), p = 0.120, ORadj = 1.93 (CI: 0.842, 4.410)]. Conclusion: Antidiabetic therapy in cirrhotic diabetic patients often seems to be inappropriate in everyday medicine, while glycemic control is frequently not satisfactory, possibly due to incompliance or insufficient metabolic control. HE occurs more often in cirrhotic patients with diabetes than in nondiabetic patients with cirrhosis. The rate of macro- and microangiopathic complications even in the diabetic cohort is low.

Journal Section:
Original Paper
Keywords:
Diabetes mellitus, Glycemic control, Hepatogenous diabetes, Impaired glucose tolerance, Cirrhosis
1.
Naunyn B: Glykosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber; in Naunyn B (ed): Der Diabetes Mellitus. Vienna, A. Holder, 1898, pp 38–49.
2.
Perseghini G, Mazzaferro V, Sereni LP, et al: Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000;31:694–703.
[PubMed]
https://doi.org/10.1002%2Fhep.510310320
3.
Shetty A, Wilson S, Kuo P, et al: Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation 2000;69:2451–2454.
[PubMed]
https://doi.org/10.1097%2F00007890-200006150-00043
4.
Holstein A, Hinze S, Thiessen E, et al: Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17:677–681.
[PubMed]
https://doi.org/10.1046%2Fj.1440-1746.2002.02755.x
5.
Petrides AS, DeFronzo RA: Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev 1989;5:691–709.
[PubMed]
https://doi.org/10.1002%2Fdmr.5610050805
6.
Petrides AS, Vogt C, Schulze-Berge D, et al: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994;19:616–627.
[PubMed]
https://doi.org/10.1002%2Fhep.1840190312
7.
Buzzelli G, Chiarantini E, Cotrozzi G, et al: Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver 1988;8:354–359.
[PubMed]
8.
Niederau C, Fischer R, Pürschel A, et al: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107–1119.
[PubMed]
https://doi.org/10.1053%2Fgast.1996.v110.pm8613000
9.
Hickman IJ, Macdonald GA: Impact of diabetes on the severity of liver disease. Am J Med 2007;120:829–834.
[PubMed]
https://doi.org/10.1016%2Fj.amjmed.2007.03.025
10.
Gentile S, Loguercio C, Marmo R, et al: Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Res Clin Pract 1993;22:37–44.
[PubMed]
https://doi.org/10.1016%2F0168-8227%2893%2990130-W
11.
Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al: Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009;15:280–288.
[PubMed]
https://doi.org/10.3748%2Fwjg.15.280
12.
Sigal SH, Stanca CM, Kontorinis N, et al: Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 2006;101:1490–1496.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2006.00649.x
13.
Nishida T, Tsuji S, Tsuji M, et al: Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006;101:70–75.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2005.00307.x
14.
Garcia-Tsao G: Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005;42(suppl):S85–S92.
[PubMed]
https://doi.org/10.1016%2Fj.jhep.2004.12.006
15.
El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–468.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2003.10.065
16.
Huo TI, Lui WY, Huang YH, et al: Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003;98:2293–2298.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2003.07688.x
17.
Hassan MM, Hwang LY, Hatten CJ, et al: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatol 2002;36:1206–1213.
[PubMed]
https://doi.org/10.1053%2Fjhep.2002.36780
18.
La Vecchia C, Negri E, Recarli A, et al: Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997;73:204–207.
[PubMed]
https://doi.org/10.1002%2F%28SICI%291097-0215%2819971009%2973%3A2%3C204%3A%3AAID-IJC7%3E3.0.CO%3B2-%23
19.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(suppl 1):62–69.
https://doi.org/10.2337%2Fdc11-S062
20.
Petrides AS: New aspects of the regulation of glucose metabolism in chronic liver diseases. Z Gastroenterol 1993;31(suppl 5):53–55.
[PubMed]
21.
Petrides AS: Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis. Z Gastroenterol 1999;(suppl 1):15–21.
[PubMed]
22.
Gentile S, Guarino G, Romano M, et al: A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005;3:184–191.
[PubMed]
https://doi.org/10.1016%2FS1542-3565%2804%2900667-6
23.
Ha NB, Ha NB, Ahmed A, Ayoub W, Daugherty TJ, Chang ET, Lutchman GA, Garcia G, Cooper AD, Keeffe EB, Nguyen MH: Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. Cancer Causes Control 2012;23:455–462.
[PubMed]
https://doi.org/10.1007%2Fs10552-012-9895-z
24.
Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC: Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46–52.
[PubMed]
https://doi.org/10.1038%2Fajg.2011.384
25.
Murphy EJ, Davern TJ, Shakil AO, et al: Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 2000;45:549–553.
[PubMed]
https://doi.org/10.1023%2FA%3A1005405526283
26.
Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M: Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601–2608.
[PubMed]
https://doi.org/10.1210%2Fjc.2010-2415
27.
Donadon V, Balbi M, Mas MD, Casarin P, Zanette G: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750–758.
[PubMed]
https://doi.org/10.1111%2Fj.1478-3231.2010.02223.x
28.
Kim MG, Choi WC: Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus. Korean J Hepatol 2006;12:524–529.
[PubMed]
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.